Publications by authors named "R K Parajuli"

Despite years of a national deworming campaign, the incidence of intestinal parasitic infections (IPIs) remains relatively high among certain ethnic groups, with lifestyle factors distinct from those of the general population. Despite existing studies on the prevalence of IPIs, there is limited research exploring the contextual associated factors within the Badi Indigenous community. Our objective in this study was to assess the prevalence of IPIs in the indigenous Badi community of Gurbhakot Municipality, Surkhet, Nepal, considering socioeconomic, lifestyle, and behavioral factors.

View Article and Find Full Text PDF

Background: Cardiac papillary fibroelastomas (CPFs) are benign endocardial tumours with embolic potential. This article is a systematic review to identify the clinical profile, diagnosis, tumour characteristics, and treatment modalities in patients with CPF presenting with stroke or transient ischemic attack (TIA).

Methods: This systematic review was conducted using the PubMed and Embase databases, including case reports and/or series and observational studies (for a search period of up until April 2022).

View Article and Find Full Text PDF

Background: Phytochemicals have long remained an essential component of the traditional medicine system worldwide. Advancement of research in phytochemicals has led to the identification of novel constituents and metabolites from phytochemicals, performing various vital functions ranging from antimicrobial properties to anticarcinogenic roles. This plant is traditionally used by local people to manage inflammation.

View Article and Find Full Text PDF

Inconsistent results have been obtained from studies investigating the association between soil-transmitted helminths (STHs) and nutritional status and cognitive outcomes. This study aimed to investigate the influence of STHs and nutritional status on the intelligence quotient (IQ) of adolescents in the Chitwan Valley, Nepal. In this birth cohort study from the Chitwan district of Nepal, 74 cohort participants were followed up after 14 years.

View Article and Find Full Text PDF

Purpose: Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2-negative (HER2-) ABC experience is reported here.

View Article and Find Full Text PDF